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Abstract 
The use of medicines in care homes could be improved and as a result, the health of residents 
would be better. Pharmacist prescribers (i.e. pharmacists specifically trained and qualified to 
prescribe), have been shown to provide safe, quality care in other patient groups. We 
proposed to test if making ‘pharmacist prescribers’ part of the care home team, working 
alongside general practitioners, could improve the use of medicines and the care of residents. 
These pharmacist prescribers authorised monthly prescriptions whilst carefully monitoring 
how each resident responded. We believe that such a change to the management of medicines 
in care homes is likely to be a good use of NHS money. This paper describes a series of 
developmental studies that were undertaken as part of a programme of work which followed 
the MRC Framework for developing and evaluating a complex intervention. The rationale for 
each study is described and for the final of these feasibility studies, when all components 
were tested together, we consider what went well, some of the challenges we encountered, 
and how they informed our decision to progress to a definitive randomised controlled trial.  
 
 
Learning Outcomes 
By the end of this case, students should be able to:  
• Describe the steps required before a new intervention is tested via a definitive 
randomised controlled trial (RCT) 
• Explain why preliminary feasibility work should be conducted before undertaking a 
full RCT 
• Be able to create appropriate research questions for feasibility and pilot studies 
• Report a feasibility study using the CONSORT 2010 statement: extension to 
randomised pilot and feasibility trials 
 
 
 
 
Case Study 
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Project Overview and Context 
The Problem 
Prescribing, monitoring and administration of medicines in care homes could be significantly 
improved, increasing residents’ quality and quantity of life and improving use of NHS 
resources (1). Research has identified the need for one person to assume overall responsibility 
for the management of medicines within each care home (2). 
 
The intervention 
Pharmacist independent prescribers (PIPs) (i.e. pharmacists specifically trained to prescribe 
in a similar way to doctors), have been shown to provide high quality care in other patient 
groups, which is safe and well received. (3) We proposed to test if making ‘pharmacist 
prescribers’ part of the care home team, working in partnership with a patient’s own general 
practitioner, could improve the use of medicines and the care of residents. These pharmacist 
prescribers could sign and order monthly prescriptions whilst monitoring how each resident 
responds.  
 
Hypothesis 
We believed that such a change to the management of medicines in care homes was likely to 
be a good use of NHS money.  
 
Our ultimate aim was to test this hypothesis with a cluster-randomised controlled trial 
designed in accordance with SPIRIT(4) guidance. However, to ensure that we had the best 
chance of success (i.e. recruited to target, retained participants, collected data on at least 80% 
of residents) we undertook a number of smaller linked feasibility projects in line with 
national guidance for development and delivery of complex interventions (5).   
 
Section summary 
• Prescribing of medicines in care homes is sub optimal 
• Independent prescribing pharmacists could take responsibility for patients’ 
medicines and improve outcomes of care 
• Prior to conducting a definitive randomized controlled trial  a programmer of 
feasibility work was undertaken… 
 
Research Design 
We proposed a 5 year programme of research to develop, optimise and test the innovative 
pharmacist prescriber service model.  We  started by updating our knowledge of the research 
on how best to prescribe and use medicines in care homes, especially focussing on managing 
older frail patients who take multiple medications.  We used the expertise of those working in 
care homes to find out how best to introduce and deploy pharmacist prescribers as part of the 
care home team (Work package 1 (WP1). At the same time, we needed to find the best 
outcomes to use to measure the effect of the pharmacist intervention on residents, and staff in 
the care home and GP practice. To do that, we looked at how other researchers had measured 
the effect of pharmacists in care homes and ranked those methods for suitability (WP2).  
 
Once we had identified how to introduce, run and test the new service, we had to design and 
test a training package to prepare pharmacists for this new prescribing role (WP4), before 
actually testing out the service and our recruitment and data collection in a small number of 
care homes for three months. We refer to this stage as the feasibility study (WP5). Following 
this, the main RCT began in four areas of the UK: East Anglia, Yorkshire, North-east 
Scotland and Northern Ireland (WP6).  We adopted a cluster randomised design and 
randomised by prescribing pharmacist-GP-care home triad so that we had intervention triads 
and control triads (usual care by the GP) that were geographically distinct. This was to avoid 
the threat of contamination i.e. we wanted to ensure that the intervention did not spread to our 
control group (in this case residents not receiving the intervention). Had we randomised 
residents within a care home to receive, or not receive, our intervention, it is likely that any 
improved medicine ‘systems’ would have ‘spread’ beyond our intervention patients.  As a 
result, we chose to randomise whole homes to either receive or not, our intervention.  In this 
main RCT the intervention is being delivered for 6 months. There was an initial stage called 
an internal pilot trial to confirm that we could recruit enough doctors, care homes and 
residents. Once that was assured we continued to recruit our target of 880 care home residents 
in total from 49 homes spread across four different parts of the UK. Data from the internal 
pilot phase is retained within the study data set. After six months we will compare how 
residents, staff and care homes have done in the two different groups and determine the value 
of the service for residents and the NHS. At the time of writing this main trial is still ongoing.  
 
Our programme aims and objectives are listed below, together with a reference to the Work 
Package (WP) which addresses the objective.   
 
Aim 
To determine the effectiveness and cost-effectiveness of pharmacist independent prescribing 
in care homes 
 
Objectives 
The objectives for the programme grant within the care home environment are to: 
• Update evidence regarding the optimisation of medicines use (WP1: Phase 1) 
• Obtain stakeholder views to inform the development of the service specification for a 
pharmacist independent prescriber who assumes responsibility for the management of 
prescribing (WP1: Phase 2) 
• Prepare and refine a service model and initial service specification for pharmacist 
independent prescribing (WP1: Phase 3) 
• Evaluate potential outcome measures to determine the effect of the service and 
identify the most suitable with respect to validity, reliability, utility and proximity to 
the intervention (WP2) 
• Identify how data on costs and health economic outcomes (including utility) should be 
measured (WP3).    
• Develop a training package to ensure that pharmacist independent prescribers are 
appropriately prepared to deliver the service (WP4) 
• Test and refine service specification and proposed study processes including care 
home and resident recruitment and data collection (WP5) 
• Conduct an internal pilot study to identify any likely difficulties with recruitment 
within the definitive trial (WP6) 
• Perform a definitive study to determine the effectiveness of pharmacist independent 
prescribing in care homes (WP6) 
• Estimate the cost-effectiveness of the intervention in the immediate and longer term 
(WP3) 
• Outline how a model of care and associated training package for the integration of 
pharmacist independent prescribers into care homes can be introduced and delivered 
(WP4 & WP6)  
 
In the rest of this paper, work packages 1-4 are summarised briefly before we describe in  
more detail our experiences of the feasibility study (WP5) (6) and the lessons we learned. The 
whole approach followed the MRC Framework (5) for the development and evaluation of a 
complex intervention (ie an interventions that contain several interacting components as in 
our proposed PIP led service). This approach emphasises the importance of undertaking 
preliminary work to identify the evidence base, model the process and outcomes and test 
procedures. All of these stages can be regarded as different aspects of feasibility work in 
which areas of uncertainty are explored. There is often also a stage referred to as a feasibility 
or pilot study (our WP5) in which most or all of the components are tested together (7).   
Work packages  
i) WP1: Service Specification Development 
In this workpackage we updated an existing Cochrane review (8) of the literature regarding 
optimisation of medicines’ use within care homes and undertook a further literature review to 
identify guidelines and research evidence supporting best practice in medicines 
administration and management within care homes. Based on these reviews, we developed an 
outline service specification to describe: 
a) The roles and responsibilities of the PIP 
• PIP visit frequency and availability 
• Scope of service (prescribing, ordering, storage and administration) 
• Use and role of PCPs (presentation and content) 
b) The systems and procedures to be introduced: 
• Access to medical and care records and prescribing budget 
• Integration of the PIP into the established healthcare system 
• Effective lines of communication between PIP, GP and home 
  
We then undertook, focus groups and interviews with GPs, pharmacists, care home staff and 
care home residents to explore their views on the proposed service including logistical and 
professional barriers/solutions to implementation; and the most appropriate outcome to use in 
a future trial. All proceedings were audio-recorded, transcribed verbatim and thematically 
analysed. The findings reassured us that all stakeholders were very positive about the 
proposed service and confirmed it would meet a service need. The GPs emphasised that, if 
possible, they should already have good relationships with the pharmacists and it should not 
give then extra work (9).   
  
On the basis of the stakeholder feedback details of the service specification were finalised 
and it was peer reviewed in each of the four participating regions at a one-day workshop, 
when any outstanding implementation issues were also addressed.   
  
ii) WP 2: Identification of Outcome Measures 
Many previously conducted trials of pharmacist interventions have either used a measure of 
process (eg number of changes made to a medication regime) or a condition-specific outcome 
eg blood pressure, or a generic measure such as quality of life or mortality. Using a process 
measure is limited because it does not demonstrate that the intervention has been of direct 
value to a patient, using a condition specific measure is not appropriate if the population 
includes individuals with different conditions and a generic measure such as quality of life 
can be insensitive to improvements resulting from interventions made to a medicine regime 
in old and frail populations such as those found in care homes.. Commonly-used outcome 
measures for similar interventions, such as falls and hospitalisations, also have limitations 
related to sensitivity and concerns regarding the quality of available data. We sought to 
identify valid and reliable outcomes for the care home population using a systematic 
literature review to identify potential outcome measures followed by a consensus process in 
which possible measures were assessed against predetermined criteria. The fall rate per 
person at 6 months was selected as the primary outcome measure. To address the concern 
about  quality of available data, we used the falls recorded in the Care home falls book in 
which a fall is defined as an unintentional or unexpected loss of balance resulting in coming 
to rest on the floor, the ground, or an object below knee level (10). A paper: ‘Development of 
a Core Outcome Set for effectiveness trials aimed at optimising prescribing in older adults in 
care homes’ on this work was published soon after completion of the work package. As a 
general rule we feel it is important to disseminate findings as soon as possible so others can 
make use of them.  (11).  
 
iii) WP 3: Health Economics 
The estimation of cost-effectiveness is an iterative process and consequently this work 
package was conducted alongside the feasibility study, and main study. As we were 
proposing a new service, it was anticipated that currently available resource use collection 
tools may need to be amended to ensure they captured relevant resource items. We planned to 
test our collection of cost data in the WP5 feasibility study using a combination of sources 
including care home records (length of residence; medication; visits from GP, practice/district 
nurse, and mental health practitioners); and medical records (inpatient services, outpatient 
services and A&E visits). As with any outcome data, it is important to know that the data is 
available, and can be collected reliably for all patients at all pre-specified time points. As well 
as understanding the costs involved and in line with previous research in care homes,(12) we 
anticipated using proxy EQ-5D completion as the main quality of life measure. With this 
method, the resident’s key carer, or carer looking after them on the day of data collection, 
would be asked to complete the EQ-5D-5L proxy version 2 (see http://www.euroqol.org/eq-
5dproducts/ eq-5d-5l/proxy-paper.html); those participants with capacity would also be asked 
to complete the EQ-5D-5L at both time points.  
 
iv) WP4: Training 
In contrast to a clinical trial of a drug when formulation, route of administration and dosage 
regimen are the main variables, a trial involving an intervention delivered by health care 
professional is more difficult to control in terms of consistency of the intervention. One way 
this can be at least partially addressed is to ensure those delivering the intervention have all 
been trained to a common minimal standard. In this study, a training package was designed 
based on a systematic review of the literature (13), and qualitative research. Following 
feedback from the feasibility study which is described below as work package 5, further 
small changes were made prior to the start of the main trial (Work package 6). 
 
v) WP5: Feasibility study and service specification refinement   
 
A full report of the feasibility study has been published (6) but key elements are summarised 
below followed by a reflection of what went well and what went less well and lessons 
learned.  
 
The objectives of our non randomised feasibility study were to:  
• Describe the appropriateness of and acceptability of both the service specification and 
proposed research design 
• estimate the size of the eligible population and assess the feasibility of the recruitment 
processes 
• describe the suitability of outcome measures for use in the main trial 
• estimate willingness to participate and retention rates 
 
Before delivering the intervention the PIPs received the training package developed 
previously, gave immediate written feedback and were also asked about the training in the 
post intervention focus group. They then provided the pre-defined service, to consenting 
residents for three months. Formal outcome data were collected at baseline and three months 
by researchers, local to each area. We recorded the: 
• proportion of general practices, care homes, residents approached who consented to 
participate 
• proportion of residents followed up at 3 months 
• quality and completeness of data collected at baseline and follow-up 
 
As part of this work package we undertook a process evaluation using interviews and focus 
groups with the PIPs and the other stakeholders across all sites to understand participants’ 
experiences and inform changes to ensure the success of the subsequent main study.  For 
example: was the new service acceptable, were changes to the service recommended, were 
the participant documents clear; did the arrangements for third party consent work smoothly; 
could patients be identified as proposed; and was the research burden acceptable.   
 
The feasibility study was completed successfully, reported in accordance with recent 
guidance (14) and confirmed progression to main RCT.  We confirmed that no major changes 
were needed and a protocol for the definitive trial with internal pilot was finalised (15) .   
Section summary 
• …A non randomised feasibility study was undertaken to test all the 
components of the intervention together  
• …Interviews and focus groups with participants explored the acceptability of 
the intervention and the research processes  
 Research Practicalities 
Having assembled all the building blocks it was essential to test these components together 
before embarking on a main study. At this stage it is important to consider whether this 
feasibility study should be randomised or not. If most of the uncertainty relates a central 
component other than the logistics of recruiting and randomisation it is probably best to 
undertake a non-randomised feasibility study, and to consider the challenges of 
randomisation and recruitment in an internal pilot at the next stage.  This was the approach 
that was taken in this programme of work.   
 
A feasibility study such as this needs to be large enough to be reasonably confident that the 
findings can reliably inform decisions about the next stage of the programme. Given the 
diverging nature of the NHS in the devolved countries it was agreed that the feasibility study 
needed to include all four regions. Secondly, although the professionals delivering the 
intervention are the pharmacist independent prescribers (PIPs), it is also necessary to recruit 
GPs, care homes and residents. The order in which this is done needs to be considered 
carefully. We decided that we would recruit one PIP working in each site (East Anglia, 
Yorkshire, North East Scotland and Northern Ireland) via local networks. We then used local 
research networks to identify all medical practices with links to care homes and explored 
their interest in taking part in either this feasibility study or the subsequent randomised trial.  
 
We then had to match PIPs to GPs and in accordance with earlier findings, we prioritised 
selection of practices that had an established working relationship with a PIP where that was 
possible. Subsequently the GP/PIP team approached the care home(s) to explore their interest 
in participation before their permission was obtained. In practice we used different 
approaches in each of the four study locations to map onto local arrangements. Personal 
networks facilitated identification of key contacts.   
 
Finally, we recruited 10 residents per home, 65 years old or older, on more than one regular 
medicine who gave their informed, written consent. For residents without capacity, this was 
done by proxy. The exact approach differed between Scotland, where the proxy person 
known as a Welfare Power of Attorney could consent on the resident's behalf, and the other 
three areas in which the proxy person known as a consultee was used in accordance with the 
Mental Capacity Act.  Because of this difference in mental health regulations we also had to 
seek Ethical approval from research ethics committees in both England and Scotland. The 
Scottish   
 
Section summary 
• Recruiting participants from four different inter-related populations is 
complex and ultimately needs to be adaptable to local contexts 
• There are different approaches for recruiting research participants who lack 
capacity between Scotland and other devolved countries 
 
 
Method in Action 
 
What went well 
• The feasibility study recruited to target and was completed within the scheduled time 
frame 
• The level of expressions of interest from eligible GPs confirmed sufficient 
participants for the main trial and the consent rate of residents informed the target 
number of care home patients required to be registered with the participating GP.  
• The PIPs were very satisfied with the format and content of the training package 
• The processes successfully identified and recruited trial participants (GPs, PIPs, care 
homes and residents) and retained them in the study for three months.  
• No problems were identified with the approach to recruiting participants without 
capacity, including use of consultees and welfare power of attorney.  
• A range of outcomes/outcome measures were tested and a subset verified as suitable 
for efficient collection with larger participant numbers. Some were removed because 
they were not completed well and some because they did not add anything 
• The new service was welcomed by all stakeholders. There were individual instances 
where pharmacist interventions resulted in observable improvements in an individual 
and there were suggestions from the outcome data that residents benefited (but note, 
there was no formal control group to compare changes seen against). 
• Small changes were suggested to the service specification these were not substantive 
• The PIPs participating in this study included pharmacists employed by either primary 
care or the GP practice providing evidence that this service specification is adaptable 
to either model, although PIPs with a pre-existing relationship with the GP found it 
easier to arrange meetings. 
• Reporting the study in line with recent guidance (15) ensured we remained focussed 
on feasibility objectives and did not pre and post statistical testing to assess efficacy 
 
What challenged us 
• There are differences in mental capacity regulations between Scotland and the rest of 
the UK. These affect the criteria for involving adults without capacity in studies, and 
also require Ethical Approval to be sought from a Research Ethics Committee in 
Scotland and England.  Whilst the English Research Ethics Committee approved the 
study to include adults without capacity, the Scottish committee did not. Given that 
approximately three quarters of those in care homes do not have capacity we believed 
it was essential they should be allowed to take part in the study. We had several phone 
calls and written appeals to the Scottish REC justifying the inclusion of these 
residents and finally a favourable opinion was given.  
 
• PIPs were asked to use a formal pharmaceutical care form as the basis for their 
decision making. The PIPs had contributed to the content of this form during the 
training but it was still quite complex and time-consuming to complete. Some of the 
PIPS used it more as an aide memoir for themselves and did not realise that it was 
also a source of research data. At the focus group, the work load associated with 
completing the form was highlighted. As a result, the form was simplified and at 
subsequent training events, the dual role of the form was emphasized and PIPs were 
requested to complete it as fully as possible.   Nevertheless, whilst stream-lined 
somewhat, the form has remained a ‘research burden’ and would be unlikely to 
translate in to a similar format outside our research environment. 
 
• Data on medication were collected from both the care home and the GP record. This 
is a duplication of effort. Although the records did not match exactly, as has been 
noted before, it was agreed that in the subsequent trial, the definitive source of 
medication data would be the GP record.  
 
• As a measure of safety all reported serious adverse event(s) (hospitalisations and 
deaths) were assessed for causality and potential association with the intervention by 
one of the medically qualified grant holders (RH). Given this can be a subjective 
judgement, this is open to bias and in the main study, independent GPs were 
employed to undertake this assessment following a standard protocol.  
 
• Following accepted guidance, all hospitalisations are classified as serious adverse 
events; however, in a population of care home residents, they are relatively frequent 
and their reporting represented a heavy workload. In the main study a two-stage 
Serious Adverse Event (SAE) reporting procedure was incorporated into a Safety 
Management Plan, with only those events with a plausible link to the intervention, as 
judged by the triad GP, to be reported on for further detailed review.  
 
• As a further safety measure, a random sample of eight forms (two per location) were 
selected and these were reviewed for appropriateness by one of two grant holders who 
were specialists in care of the elderly medicine. This process has been standardised to 
include grading of any concerns from no concern, through low, moderate and 
significant concern with appropriate feedback, further monitoring and ultimately PIP 
withdrawal if needed.  
 
Section summary 
• Overall the feasibility study went well and confirmed progression to the 
randomised controlled trial  
• The further qualitative work informed nuanced changes to some of the 
processes such as the training package and the record keeping … 
• Measures of monitoring the safety of the intervention were developed… 
 
 
Practical Lessons Learned 
The time invested in the early work packages was critical to the success of the feasibility 
study. Not only is it important to build on previous work, hence the systematic reviews, 
but it is also important to test the perceived need for the new service with stakeholders in 
the actual study context. Further, where possible, additional requests should be 
accommodated in the service specification. As one GP said to us in the early interviews, 
‘there has to be something in it for me’.  
 
We had nonacademic members as fellow grant holders (see acknowledgements below) 
representing service pharmacists, care home management, and lay representatives. They 
really helped us in working up the study details at grant application stage and post 
funding once we had secured the award. They gave helpful advice on the patient 
perspective at all stages of ongoing study conduct. Nonetheless their involvement needs 
to be well supported for it to be meaningful. In our case we always gave our patient 
representatives extra time and met with them separately to make sure they had protected 
time to discuss issues outwith more formal grant holder meetings16.  
 
It is important to check out any differences in regulations as soon as possible when 
undertaking a multisite study involving the devolved nations. Securing Ethical approval 
to involve adults without capacity became a very long drawn out process because of these 
differences. Despite all grant holders having worked with these type of participants before 
there were subtle changes to regulations which added complexity to the process 
 
Despite the research team having considerable experience of undertaking this sort of 
study a feasibility study was essential.  It is always important to remember that sitting at a 
desk and designing a study can never preempt the practicalities. Our early work suggested 
GPs would prefer to work with pharmacists they already knew and had worked with 
closely but in reality because of differences in implementation of both pharmacists 
prescribing and practice based pharmacists there was a smaller pool of eligible PIPS than 
expected. Further in some areas where there were eligible pharmacists in post in GP 
practices, their time was already committed to other priorities, so their line manager 
would not endorse their participation. Therefore recruitment approaches had to be 
modified to suit local need.  
 
In order to reassure those reviewing the protocol for ethical and R and D we included 
labour intensive safety monitoring approaches. However given the life expectancy of the 
care home population hospitalizations and deaths are far more frequent than in the general 
population and so we adapted the standard definition of a serious adverse event to take 
this into account in the planning for the subsequent trial. All such changes were approved 
by submitting amendments to the relevant ethical committees.   
 
 
Section summary 
• Local contexts, across different organizational units, may affect planned 
procedures and where possible should be understood before submitting applications for 
funding, ethics or R and D. 
• Feasibility work is always important even when teams are experienced and 
have conducted recent work in similar settings … 
• Public and patient involvement can improve planning and patient facing 
materials 
 
 Conclusion 
Having the luxury of a programme grant with a planned iterative set of work packages 
has allowed us to work up all aspects of the study prior to testing them together in the 
feasibility study reported above. The subsequent definitive trial is now in progress. We 
have worked efficiently by building on our own earlier work and that of others as well as 
undertaking new primary data collection where necessary to inform our own programme. 
This includes for example the preliminary interviews with stakeholders to assess their 
perception of the need for the programme.  It also includes the learning needs assessment 
we undertook, including further systematic review, prior to developing the training 
package. It is important to be sure that where the active component of the intervention is a 
health care professional that they are all competent to provide the services as planned. We 
have also published the outputs from each stage to ensure our research findings have 
greater value by being made available to the wider research community. No randomized 
controlled trial should be conducted without such underpinning work which should be 
planned in accordance with the MRC Framework.  
 
Section summary 
• Feasibility work is essential prior to undertaking a definitive trial … 
• Previous research on a topic should always be taken into account in any new 
proposals … 
 
 
 
Classroom Discussion Questions 
1. What are the benefits of looking at the literature in a systematic manner before embarking on a 
project of this nature? 
2. What actions were taken by the team to increase the likelihood of the service being acceptable? 
Could these have been done differently  
3. Why do you believe Falls was selected as the main outcome measure in this study? Consider 
issues with this outcome and why data on falls may not be considered ‘ideal’ or ‘perfect’.   
4. Reflect on reasons why despite the good recruitment and retention of all stakeholders in this study, 
this might not be reproduced in a larger study with a longer intervention period. What could be done to 
mitigate these?  
5. Discuss what uncertainties still remain that need to be explored in the internal pilot trial. What are 
they and how could they be tested. What happens if the internal pilot study identified major 
recruitment problems? 
 
 
 
Multiple Choice Quiz Questions 
1. The purpose of a feasibility study is to:  
A. Address uncertainties in proposed trial design (CORRCET)  
B. Confirm intervention acceptability 
C Confirm intervention efficacy 
 2. When applying for Ethical approval you should: 
A Always apply to each participating devolved nation  
B. Apply to each participating devolved nation only for certain categories of 
participants (CORRECT) 
C. Use the centralized UK service to apply to one ethics committee only  
 
3. The primary outcome for a health care intervention should be; 
A. A process measure  
B. Any clinical measure  
C. A validated clinical measure (CORRECT).  
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